Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Fase I/II-studie av ONC-PluReceptor NK-celler med epcoritamab og tafasitamab for pasienter med tilbakevendende eller refraktær B-celle ikke-Hodgkin lymfom

31. oktober 2026 oppdatert av: M.D. Anderson Cancer Center

Fase I/II-studie av ONC-PluReceptor NK-celler med epcoritamab og tafasitamab for pasienter med tilbakevendende eller refraktær B-celle non-Hodgkin lymfom

The goal of this clinical research study is to learn if ONC-PluReceptor NK cell therapy (combined with the monoclonal antibody therapies epcoritamab and tafasitamab) can help to control relapsed or refractory B-cell Non-Hodgkin Lymphoma. The safety of this treatment will also be studied.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Primary Objective:

To establish the safety and recommended phase II dose (RP2D) of umbilical cord blood (CB)- derived natural killer (NK) cells transduced with ONC-PluReceptor (CD3 complex/IL-15) in combination with epcoritamab and tafasitamab for patients with relapsed/refractory (R/R) CD19/CD20-positive B-cell non-Hodgkin lymphomas.

Secondary Objectives:

  1. To evaluate the overall response rate (ORR), complete response (CR) rate and partial response (PR) rate of patients treated at the RP2D.
  2. To evaluate the duration of response (DOR).
  3. To evaluate the progression-free survival (PFS) rate.
  4. To evaluate the overall survival (OS) time.
  5. To quantify the persistence of infused donor NK cells in the recipient.
  6. To conduct comprehensive immune reconstitution studies.

Studietype

Intervensjonell

Registrering (Antatt)

30

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Texas
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • The University of Texas M. D. Anderson Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yago Nieto, MD,PHD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Patients with R/R DLBCL or FL with all of the following:

    Failure of >/= 2 prior lines of therapy, or an autologous or allogeneic stem cell transplant.

    Prior failure of CAR-T or not eligible for CAR-T cells.

  2. Tumor biopsy positive for CD19 or CD20 at >/= 1% by immunohistochemistry or flow cytometry.

  3. Age 18-80 years.

  4. Karnofsky performance status >/=60%.

  5. Absolute neutrophil count >/=500/mm3 and platelet count >/=50,000/mm3.

  6. Serum creatinine clearance (CrCl) >/=30 ml/min, estimated using the Cockcroft-Gault equation:

    Estimated creatinine clearance = (140-age [years]) x weight (kg) (x Fa) / serum creatinine (mg/dL) x 72 [a where F=0.85 for females and F=1 for males].

  7. Adequate hepatic function (ALT and/or AST </=3 x upper limit of normal (ULN); bilirubin and ALP </=2 x ULN). Patients with cancer involvement of the liver and elevation of ALT, AST, bilirubin, and/or ALP </= 5 x ULN are eligible, per PI discretion.

  8. Adequate pulmonary function with FEV1, FVC and DLCO (corrected for hemoglobin and volume) >/=50%.

  9. Adequate cardiac function with left ventricular ejection fraction >/=40%, and no uncontrolled arrhythmias or symptomatic cardiac disease.

  10. If female of child-bearing potential, she must not be pregnant or breastfeeding and required to have a negative urine or serum pregnancy test prior to enrollment.

  11. Female participants of non-childbearing potential must meet at least one of the following criteria:

    i. Postmenopausal (no menses in greater than or equal to 12 consecutive months).

    ii. History of hysterectomy or bilateral salpingo-oophorectomy. iii. Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).

    o Subjects who are of childbearing potential, sexually active, and at risk of pregnancy must agree to use a highly effective method of contraception for the duration of the active treatment and at least 3 months post-completion of the study therapy. See Appendix B. Highly effective methods of contraception include the following:

    iv. Hormonal contraception (i.e., birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

    o Men treated or enrolled in this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study agent administration. Men who are able to have children must use effective birth control while in the study. If the male participant fathers a child or suspects that he has fathered a child while in the study, he must immediately notify his doctor.

  12. Agree to sign the consent to the long-term follow-up protocol PA17-0843 to fulfill the institutional responsibilities to various regulatory agencies

Exclusion Criteria:

  1. Lymphoma in CR with no measurable sites of disease.
  2. Major surgery <4 weeks prior to first dose of study drug.
  3. Any other severe or uncontrolled disease or condition that might increase the risk associated with study participation.
  4. Any other malignancy known to be active, with the exception of treated cervical intra-epithelial neoplasia and non-melanoma skin cancer.
  5. Grade >/= 3 non-hematologic toxicity from prior therapy that has not improved to grade </= 2.
  6. Active hepatitis B, either active carrier (HBsAg +) or viremic (HBV DNA.>/=10,000 copies/mL, or >/=2,000 IU/mL), or hepatitis C (detectable viral load by HCV RNA PCR)
  7. Active infection requiring parenteral antibiotics.
  8. HIV infection.
  9. Treatment within prior 2 weeks with any anti-cancer agent, investigational or approved.
  10. Active central nervous system (CNS) involvement (untreated parenchymal brain metastasis or positive cytology of cerebrospinal fluid).
  11. Life expectancy </= 6 months.
  12. Active and uncontrolled neurological disorder.
  13. Patients receiving systemic steroid therapy at the time of enrollment (physiological substitutive doses are allowed), or have received antithymocyte globulin or lymphocyte immune globulin within 14 days of enrollment or alemtuzumab within 28 days of enrollment.
  14. Patients receiving immunosuppressive therapy.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Sykel 2: Dosisøkning / Dosisutvidelsesbehandling med ONC-PluReseptor NK-celler

Given by injection

Eksperimentell: ESC/EXP1_Syklus 1: Dosiseskalering / Dosisutvidelsesbehandling med ONC-PluReseptor NK-celler

Given by injection

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety and Adverse Events (AEs)
Tidsramme: Through study completion; an average of 1 year.

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Through study completion; an average of 1 year.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Yago Nieto, MD,PHD, M.D. Anderson Cancer Center

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

24. februar 2026

Primær fullføring (Antatt)

30. september 2031

Studiet fullført (Antatt)

30. september 2033

Datoer for studieregistrering

Først innsendt

11. desember 2025

Først innsendt som oppfylte QC-kriteriene

11. desember 2025

Først lagt ut (Faktiske)

16. desember 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

31. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2024-0257
  • NCI-2025-09213 (Annen identifikator: NCI-CTRP Clinical Trials Registry)

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .